Back to Journals » Therapeutics and Clinical Risk Management » Volume 14
- Houdahspot 3 9 – Advanced Front End For Spotlight
- Houdahspot 3 9 – Advanced Front End For Spotlight Trailer
- Houdahspot 3 9 – Advanced Front End For Spotlight Lighting
- Houdahspot 3 9 – Advanced Front End For Spotlight Light
HoudahSpot 3.9 – Advanced front-end for Spotlight. August 7, 2014 HoudahSpot is an advanced file search utility based upon the powerful MacOS X Spotlight database. Targeted treatment of advanced ovarian cancer: spotlight on rucaparib Diana C Pearre, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics &; Gynecology, University of California, Irvine Medical Center, Orange, CA, USA Abstract: The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Administration’s (FDA) approval of poly. 'HoudahSpot is the front end most Spotlight users don't know they're missing!' HoudahSpot unleashes the power of Spotlight. It makes good on the promise of quickly finding the files you search for. Create detailed queries to pinpoint the exact file you want to get to.
- We're Houdah Software. We handcraft applications for Mac, iPhone & iPad. We are best known for HoudahSpot and HoudahGeo. Established 2005.
- Elfeland RGB LED Spotlight LED Closet Lights with Remote, Dimmable Battery Operated Accent Lights with Rotatable Light Head Stick on Anywhere for Lighting up Painting Picture Artwork Closet (2 Pack) 4.3 out of 5 stars 199. $2.00 coupon applied at checkout Save $2.00 with coupon.
AuthorsPearre DC, Tewari KS
Received15 June 2018
Accepted for publication 24 September 2018
Published 2 November 2018 Volume 2018:14 Pages 2189—2201
DOIhttps://doi.org/10.2147/TCRM.S149248
Checked for plagiarism Yes
Review bySingle anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Garry Walsh
Houdahspot 3 9 – Advanced Front End For Spotlight
Diana C Pearre, Krishnansu S Tewari
Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine Medical Center, Orange, CA, USA
Abstract: The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Administration’s (FDA) approval of poly-ADP ribose polymerase (PARP) inhibitors (PARPi). One of the deadliest cancers that women experience, ovarian cancer, is most often diagnosed in advanced stages. Although cytoreductive surgery and (platinum/taxane-based) chemotherapy can place the majority of patients into remission, most will experience a relapse of their disease in their lifetime. This has led to studies exploring the benefits and efficacy of maintenance treatment. This review will briefly discuss the history of maintenance therapy as well as focus on the FDA’s approval of rucaparib and its companion tumor profiling test, in the US. It will describe how women with deleterious mutations in the BRCA gene, through their inherent deficiency in homologous recombination, presented scientists with a target to exploit through a concept known as synthetic lethality. Not only did this lead to a targeted treatment for BRCA mutation carriers but for other patients with deficiencies in homologous recombination and, more broadly, also in platinum-sensitive patients. The focus of this review will be on rucaparib in the US, approved for both maintenance of platinum-sensitive recurrent ovarian cancer and treatment in the third-line setting and beyond. It has the broadest indication amongst the three PARPi in ovarian cancer. Furthermore, the ongoing trials using rucaparib in ovarian cancer and other disease types will be discussed.
Keywords: BRCA, PARP inhibitor, targeted therapy, rucaparib, ovarian cancer
Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine Medical Center, Orange, CA, USA
Abstract: The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Administration’s (FDA) approval of poly-ADP ribose polymerase (PARP) inhibitors (PARPi). One of the deadliest cancers that women experience, ovarian cancer, is most often diagnosed in advanced stages. Although cytoreductive surgery and (platinum/taxane-based) chemotherapy can place the majority of patients into remission, most will experience a relapse of their disease in their lifetime. This has led to studies exploring the benefits and efficacy of maintenance treatment. This review will briefly discuss the history of maintenance therapy as well as focus on the FDA’s approval of rucaparib and its companion tumor profiling test, in the US. It will describe how women with deleterious mutations in the BRCA gene, through their inherent deficiency in homologous recombination, presented scientists with a target to exploit through a concept known as synthetic lethality. Not only did this lead to a targeted treatment for BRCA mutation carriers but for other patients with deficiencies in homologous recombination and, more broadly, also in platinum-sensitive patients. The focus of this review will be on rucaparib in the US, approved for both maintenance of platinum-sensitive recurrent ovarian cancer and treatment in the third-line setting and beyond. It has the broadest indication amongst the three PARPi in ovarian cancer. Furthermore, the ongoing trials using rucaparib in ovarian cancer and other disease types will be discussed.
Keywords: BRCA, PARP inhibitor, targeted therapy, rucaparib, ovarian cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Download Article [PDF]View Full Text [HTML][Machine readable]© Motor1.com Copyright Toyota Aygo new spy photo (front three-quarters)
Testing with a soft top in cold weather.
Late in 2019, we got a confirmation that Toyota won’t discontinue the Aygo once the current generation of the model goes out of production. Approximately a year later, we caught an early prototype of the new Aygo testing on public roads and today we can share a full gallery with the new A-segment car.
Spied testing in winter conditions somewhere in Northern Europe, the new Aygo seems to be in the advanced stages of its development. The test car has a lot of camouflage but it can’t hide what looks like a production body, headlights, and taillights.
If you are wondering why the roof is black, the answer is very simple and it doesn’t include any custom or two-tone exterior paints. Instead, this prototype rocks a canvas roof which is going to be available as an option for the next-gen model. As a reminder, the current Aygo is also offered with a foldable soft top in Europe.
Houdahspot 3 9 – Advanced Front End For Spotlight Trailer
There were early rumours about the Aygo switching from its hatchback shape to some sort of a lifted hatch but that doesn’t seem to be the case judging by these spy shots. They reveal the model will carry over with a traditional hatch body style and a four-door arrangement. The first impressions are for a slightly bigger car than the outgoing model though.
Houdahspot 3 9 – Advanced Front End For Spotlight Lighting
New Aygo spied and rendered:
Toyota seems to be on its own in the development of the new Aygo as PSA is reportedly abandoning the segment with its Citroen C1 and Peugeot 107 twins. The Japanese automaker sees this as “an opportunity to go further, not pull back,” as the Aygo is still selling very well in Europe despite its age.
At launch, the new Aygo will be available with a petrol engine but a fully-electric version is reportedly also in the works. We’ll find out more in the coming months as the overhauled A-segment entry should be launched towards the end of the year.
Houdahspot 3 9 – Advanced Front End For Spotlight Light
Source: CarPix